Daily Judi: Wednesday, October 5, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Including new therapeutics from Gilead and Apellis, BioPharma Dive looks at five decisions of interest the United States Food and Drug Administration may make in the fourth quarter.
An early-stage clinical trial has begun evaluating the safety of bacteriophage therapy in adults with cystic fibrosis who have Pseudomonas aeruginosa in their lungs. Conducted by the Antibacterial Resistance Leadership Group, and funded by the National Institute of Allergy and Infectious Diseases, the study will enroll up to 72 adults at 16 sites in the United States. (National Institutes of Health)
Daniel Lehewych examines the growing use and applications of nanophotonic devices in clinical research. (Medical Device Network)
The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!
Our Culture
“We create a template so we can pull back the timelines and eliminate concerns around quality and risk—because everything’s already validated in the design. Then we can work faster with no risk to quality.”
–Jamie, Trial Delivery
About Judi
Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
